Invention Grant
US07812167B2 Substituted (thiazol-2-yl)-amides or sulfonamides as glucokinase activators useful in the treatment of type 2 diabetes
失效
作为可用于治疗2型糖尿病的葡萄糖激酶激活剂的取代的（噻唑-2-基） - 酰胺或磺酰胺
- Patent Title: Substituted (thiazol-2-yl)-amides or sulfonamides as glucokinase activators useful in the treatment of type 2 diabetes
- Patent Title (中): 作为可用于治疗2型糖尿病的葡萄糖激酶激活剂的取代的（噻唑-2-基） - 酰胺或磺酰胺
-
Application No.: US10529670Application Date: 2003-10-02
-
Publication No.: US07812167B2Publication Date: 2010-10-12
- Inventor: Gregory Raymond Bebernitz
- Applicant: Gregory Raymond Bebernitz
- Applicant Address: CH Basel
- Assignee: Novartis, AG
- Current Assignee: Novartis, AG
- Current Assignee Address: CH Basel
- Agent Theresa Devlin
- International Application: PCT/EP03/10977 WO 20031002
- International Announcement: WO2004/050645 WO 20040617
- Main IPC: A61K31/426
- IPC: A61K31/426 ; A61K31/429 ; C07D277/46 ; C07D277/52 ; C07D513/02
Abstract:
Compounds of the formula R—NH-Q (I) provide pharmacological agents which are glucokinase activators and thus may be employed for the treatment of glucokinase mediated conditions. Accordingly, the compounds of formula (I) may be employed for prevention and treatment of impaired glucose tolerance, Type 2 diabetes and obesity.
Public/Granted literature
Information query
IPC分类:
